
Integrum - Solid performance in Q4

Redeye returns with a more in-depth take on the Q4'21/22 report and is encouraged that Integrum demonstrated significant sales growth. We believe its US focus will show even better results as we advance throughout the year, thanks to its intensified activities and as the pandemic eases up for elective surgeries.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Integrum - Solid performance in Q4